1. Abiraterone-induced rhabdomyolysis: A case report. (March 2017) Authors: Moore, Donald C; Moore, Andrew Journal: Journal of oncology pharmacy practice Issue: Volume 23:Number 2(2017) Page Start: 148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia: A review. (December 2021) Authors: Moore, Donald C Journal: Journal of oncology pharmacy practice Issue: Volume 27:Number 8(2021) Page Start: 1993 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Caplacizumab: an anti–von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura. (26th June 2020) Authors: Hollifield, Alyssa L; Arnall, Justin R; Moore, Donald C Journal: American journal of health-system pharmacy Issue: Volume 77:Number 15(2020) Page Start: 1201 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Cost savings analysis and toxicity audit of a bevacizumab dose rounding policy at a community cancer center. (January 2018) Authors: Moore, Donald C; McVey, Gary Neal Journal: Journal of oncology pharmacy practice Issue: Volume 24:Number 1(2018) Page Start: 42 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Evaluation of a pharmacist-driven rapid infusion rituximab conversion protocol at a multisite cancer center. (December 2021) Authors: Moore, Donald C; Gebru, Tsion; Plesca, Dragos Journal: Journal of oncology pharmacy practice Issue: Volume 27:Number 8(2021) Page Start: 1914 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia. (July 2021) Authors: DiSogra, Kristyn Y; Tran, Thuy; Arnall, Justin R; Janes, Amanda; Moore, Donald C; Park, Steven I Journal: Journal of oncology pharmacy practice Issue: Volume 27:Number 5(2021) Page Start: 1265 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Impact of obesity on safety outcomes and treatment modifications with ado-trastuzumab emtansine in breast cancer patients. (January 2022) Authors: Lee, Anna; Larck, Chris; Moore, Donald C Journal: Journal of oncology pharmacy practice Issue: Volume 28:Number 1(2022) Page Start: 49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Incidence and management of adverse events associated with panobinostat in the treatment of relapsed/refractory multiple myeloma. (April 2019) Authors: Moore, Donald C; Arnall, Justin R; Harvey, R Donald Journal: Journal of oncology pharmacy practice Issue: Volume 25:Number 3(2019) Page Start: 613 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Measuring the Impact of a Pharmacist-Driven Blood Factor Education Program: A Prospective, Single-Center Observational Study. (June 2023) Authors: Arnall, Justin R; Moore, Donald C; Michael, Meghan; Wolcott, Michael; Cowgill, Nicole Journal: Hospital pharmacy Issue: Volume 58:Number 3(2023) Page Start: 282 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Necitumumab for the treatment of squamous cell non-small cell lung cancer. (January 2018) Authors: Brinkmeyer, Jessica K; Moore, Donald C Journal: Journal of oncology pharmacy practice Issue: Volume 24:Number 1(2018) Page Start: 37 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗